Cliff Asness's PHAT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 55,468 shares of Phathom Pharmaceuticals, Inc. (PHAT) worth $616,249, representing 0.00% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in PHAT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 89,741 shares. Largest reduction occurred in Q2 2025, reducing 57,475 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Phathom Pharmaceuticals (PHAT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Phathom Pharmaceuticals (PHAT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1,020 | Add 1.87% | 55,468 | $11.11 |
| Q4 2025 | +1,819 | Add 3.46% | 54,448 | $16.59 |
| Q3 2025 | +2,705 | Add 5.42% | 52,629 | $11.77 |
| Q2 2025 | -57,475 | Reduce 53.52% | 49,924 | $9.59 |
| Q1 2025 | +89,741 | Add 508.22% | 107,399 | $6.27 |
| Q4 2024 | +17,658 | New Buy | 17,658 | $8.12 |
| Q1 2024 | -18,427 | Sold Out | 0 | $0.00 |
| Q4 2023 | -4,408 | Reduce 19.30% | 18,427 | $9.13 |
| Q3 2023 | +22,835 | New Buy | 22,835 | $10.37 |
| Q1 2023 | -10,046 | Sold Out | 0 | $0.00 |
| Q4 2022 | +10,046 | New Buy | 10,046 | $11.22 |
Cliff Asness's Phathom Pharmaceuticals Investment FAQs
Cliff Asness first purchased Phathom Pharmaceuticals, Inc. (PHAT) in Q4 2022, acquiring 10,046 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Phathom Pharmaceuticals, Inc. (PHAT) for 11 quarters since Q4 2022.
Cliff Asness's largest addition to Phathom Pharmaceuticals, Inc. (PHAT) was in Q1 2025, adding 107,399 shares worth $673,392.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 55,468 shares of Phathom Pharmaceuticals, Inc. (PHAT), valued at approximately $616,249.
As of the Q1 2026 filing, Phathom Pharmaceuticals, Inc. (PHAT) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Phathom Pharmaceuticals, Inc. (PHAT) was 107,399 shares, as reported at the end of Q1 2025.